Strides Pharma Science Limited (BSE: 532531, NSE: STAR) today announced that its formulation facility in Bangalore underwent a USFDA inspection that ended on May 24th, 2019. The inspection was completed successfully with a Voluntary Action Indicated (VAI) classification.
The flagship facility in Bangalore is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids. The facility services the key regulated markets of the US, Europe, and Australia.
Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.347.75 as compared to the previous close of Rs. 362.35. The total number of shares traded during the day was 74929 in over 1143 trades.
The stock hit an intraday high of Rs. 366 and intraday low of 346.65. The net turnover during the day was Rs. 26624907.